Understanding and addressing risks of low socioeconomic status and diabetes for heart failure
了解和解决低社会经济地位和糖尿病导致心力衰竭的风险
基本信息
- 批准号:10494185
- 负责人:
- 金额:$ 69.42万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2021
- 资助国家:美国
- 起止时间:2021-09-24 至 2026-06-30
- 项目状态:未结题
- 来源:
- 关键词:
项目摘要
Summary
Heart failure (HF) is associated with high morbidity, mortality and costs, and there is great interest in refining
strategies to reduce HF risk. Diabetes (DM) and low socioeconomic status (SES) are each independent risk
factors for HF, and both factors together have a synergistic association with incident HF. A major functional
consequence of these associations is impaired cardiorespiratory fitness, with implications for prognosis and
quality of life. Additionally, low SES and DM are over-represented among racial and ethnic minorities and
therefore a cause of HF disparities. Strategies to address the high HF risk associated with the combination of
low SES and DM will require a focus on social determinants of health. Problem-solving training and community
health worker (CHW) support are effective in overcoming barriers to care, and improving lifestyle, DM self-
management, health system engagement and risk factor control, but they have not yet been applied to
addressing HF risk. Prevention efforts would be further informed by understanding geographic disparities in HF
risk and elucidating clinical risk factors that might serve as targets for intervention. We therefore propose a
randomized trial among 350 persons with low SES, DM, obesity and early cardiac dysfunction, testing the
effects of a multi-level intervention of problem-solving training, CHW support and partnership with community
facilities to support lifestyle change on fitness, risk factor control, markers of cardiac injury/fibrosis and quality
of life. We propose: Aim 1: To use electronic medical record data to a) compare the association of
neighborhood SES with incident HF in patients with DM, across urban, rural and suburban settings,
and b) to identify modifiable clinical risk factors for HF associated with DM that are more prevalent in
persons with low SES. Aim 2: To adapt an evidence-based, pragmatic intervention to improve
functional status and risk factor control in persons with low SES, DM, obesity and early cardiac
dysfunction, using community-based participatory research (CBPR) and patient-centered outcomes
research (PCOR) principles. Aim 3: To test, in a randomized controlled trial, if a 1-year multilevel
intervention of problem-solving training, CHW use to enhance social support and health system
engagement, and use of community facilities to support lifestyle change improves cardiorespiratory
fitness and related outcomes in those with low SES, DM, obesity and early cardiac dysfunction, more
than enhanced education and connection with community health programs. This work will elucidate
strategies to address HF risk related to low SES and DM, which are key contributors to HF disparities.
总结
心力衰竭(HF)与高发病率、死亡率和成本相关,并且存在对精炼的极大兴趣
降低HF风险的策略。糖尿病(DM)和低社会经济地位(SES)是各自独立的风险
HF的因素,并且两个因素一起与HF事件具有协同关联。主要功能
这些关联的后果是心肺功能受损,对预后和
生活质量此外,低社会经济地位和糖尿病在少数种族和族裔中的比例过高,
因此是HF差异的原因。解决与以下组合相关的高HF风险的策略
低社会经济地位和糖尿病将需要关注健康的社会决定因素。解决问题的培训和社区
卫生工作者(CHW)支持在克服护理障碍、改善生活方式、DM自我
管理、卫生系统参与和风险因素控制,但尚未应用于
应对HF风险。通过了解HF的地理差异,将进一步了解预防工作
风险和阐明可能作为干预目标的临床风险因素。因此,我们建议
在350名低SES、DM、肥胖和早期心功能不全患者中进行的随机试验,
解决问题培训、社区卫生工作支持和与社区合作的多层次干预的效果
支持生活方式改变的设施,包括健身、风险因素控制、心脏损伤/纤维化标志物和质量
生命我们提出:目的1:使用电子病历数据,a)比较
在城市、农村和郊区环境中,DM患者发生HF的社区SES,
和B)确定与DM相关的HF的可改变的临床风险因素,
社会经济地位低的人。目标2:采用循证、务实的干预措施,
低SES、DM、肥胖和早期心脏病患者的功能状态和危险因素控制
功能障碍,使用基于社区的参与性研究(CBPR)和以患者为中心的结果
变革和组织振兴方案(变革和组织振兴方案)原则。目标3:在随机对照试验中测试1年多水平是否
问题解决训练、CHW用于增强社会支持和卫生系统干预
参与和使用社区设施来支持生活方式的改变,
低SES、DM、肥胖和早期心功能不全患者的健康和相关结局,
而不是加强教育和与社区健康项目的联系。这项工作将阐明
解决与低SES和DM相关的HF风险的策略,这是HF差异的关键因素。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Chiadi E Ndumele其他文献
Chiadi E Ndumele的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Chiadi E Ndumele', 18)}}的其他基金
Understanding and addressing risks of low socioeconomic status and diabetes for heart failure
了解和解决低社会经济地位和糖尿病导致心力衰竭的风险
- 批准号:
10658914 - 财政年份:2021
- 资助金额:
$ 69.42万 - 项目类别:
Understanding and addressing risks of low socioeconomic status and diabetes for heart failure
了解和解决低社会经济地位和糖尿病导致心力衰竭的风险
- 批准号:
10437340 - 财政年份:2021
- 资助金额:
$ 69.42万 - 项目类别:
Elucidating the Role of Adipokines in Mediating and Predicting HF Associated with Obesity
阐明脂肪因子在调节和预测肥胖相关心力衰竭中的作用
- 批准号:
9883039 - 财政年份:2019
- 资助金额:
$ 69.42万 - 项目类别:
Elucidating the Role of Adipokines in Mediating and Predicting HF Associated with Obesity
阐明脂肪因子在调节和预测肥胖相关心力衰竭中的作用
- 批准号:
10378050 - 财政年份:2019
- 资助金额:
$ 69.42万 - 项目类别:
Elucidating the Role of Adipokines in Mediating and Predicting HF Associated with Obesity
阐明脂肪因子在调节和预测肥胖相关心力衰竭中的作用
- 批准号:
10610368 - 财政年份:2019
- 资助金额:
$ 69.42万 - 项目类别:
The Relationship of Obesity with Subclinical Myocardial Injury and Heart Failure
肥胖与亚临床心肌损伤和心力衰竭的关系
- 批准号:
8679114 - 财政年份:2014
- 资助金额:
$ 69.42万 - 项目类别:
The Relationship of Obesity with Subclinical Myocardial Injury and Heart Failure
肥胖与亚临床心肌损伤和心力衰竭的关系
- 批准号:
8829697 - 财政年份:2014
- 资助金额:
$ 69.42万 - 项目类别:
相似海外基金
Therapeutic efficacy of dapagliflozin, a selective inhibitor of sodium–glucose co-transporter type 2, for chronic heart failure in Japanese patients with type 2 diabetes mellitus
选择性钠抑制剂达格列净的治疗效果
- 批准号:
23K06224 - 财政年份:2023
- 资助金额:
$ 69.42万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Use of the inhibitors of sodium-glucose cotransporter 2 in patients with different heart failure phenotypes and with type 2 diabetes mellitus
钠-葡萄糖协同转运蛋白2抑制剂在不同心力衰竭表型和2型糖尿病患者中的应用
- 批准号:
456458270 - 财政年份:2021
- 资助金额:
$ 69.42万 - 项目类别:
WBP Fellowship
A novel non-invasive device for screening and optimized management to improve heart failure outcomes in patients with diabetes mellitus
一种新型非侵入性设备,用于筛查和优化管理,以改善糖尿病患者的心力衰竭结果
- 批准号:
10274732 - 财政年份:2020
- 资助金额:
$ 69.42万 - 项目类别:
A novel non-invasive device for screening and optimized management to improve heart failure outcomes in patients with diabetes mellitus
一种新型非侵入性设备,用于筛查和优化管理,以改善糖尿病患者的心力衰竭结果
- 批准号:
10397163 - 财政年份:2020
- 资助金额:
$ 69.42万 - 项目类别:
Fibroblast Growth Factor-23 and Klotho in Heart Failure and Type 2 Diabetes Mellitus
成纤维细胞生长因子 23 和 Klotho 在心力衰竭和 2 型糖尿病中的作用
- 批准号:
327118332 - 财政年份:2016
- 资助金额:
$ 69.42万 - 项目类别:
Research Fellowships
Therapeutic strategy for ischemic heart failure with diabetes mellitus
糖尿病合并缺血性心力衰竭的治疗策略
- 批准号:
15K09143 - 财政年份:2015
- 资助金额:
$ 69.42万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
THE SYNTHESIS AND PRECLINICAL STUDIES OF NEW TREATMENTS FOR NEURODEGENERATIVE DISEASE, DIABETES MELLITUS, CONGESTIVE HEART FAILURE, ONCOLOGIC AND IMMUNOLOGIC DISEASES
神经退行性疾病、糖尿病、充血性心力衰竭、肿瘤和免疫疾病新疗法的综合和临床前研究
- 批准号:
8930676 - 财政年份:2014
- 资助金额:
$ 69.42万 - 项目类别:
THE SYNTHESIS AND PRECLINICAL STUDIES OF NEW TREATMENTS FOR NEURODEGENERATIVE DISEASE, DIABETES MELLITUS, CONGESTIVE HEART FAILURE, ONCOLOGIC AND IMMUNOLOGIC DISEASES
神经退行性疾病、糖尿病、充血性心力衰竭、肿瘤和免疫疾病新疗法的综合和临床前研究
- 批准号:
8930681 - 财政年份:2014
- 资助金额:
$ 69.42万 - 项目类别:
THE SYNTHESIS AND PRECLINICAL STUDIES OF NEW TREATMENTS FOR NEURODEGENERATIVE DISEASE, DIABETES MELLITUS, CONGESTIVE HEART FAILURE, ONCOLOGIC AND IMMUNOLOGIC DISEASES
神经退行性疾病、糖尿病、充血性心力衰竭、肿瘤和免疫疾病新疗法的综合和临床前研究
- 批准号:
9200920 - 财政年份:2014
- 资助金额:
$ 69.42万 - 项目类别:
THE SYNTHESIS AND PRECLINICAL STUDIES OF NEW TREATMENTS FOR NEURODEGENERATIVE DISEASE, DIABETES MELLITUS, CONGESTIVE HEART FAILURE, ONCOLOGIC AND IMMUNOLOGIC DISEASES
神经退行性疾病、糖尿病、充血性心力衰竭、肿瘤和免疫疾病新疗法的综合和临床前研究
- 批准号:
8930677 - 财政年份:2014
- 资助金额:
$ 69.42万 - 项目类别:














{{item.name}}会员




